
    
      This is a multi-center, randomized, open-label, two-sequence, cross-over study for eligible
      subjects with high-risk neuroblastoma to assess the comparability of ch14.18 manufactured
      with UTC drug product and ch14.18 manufactured with NCI drug product. Subjects will be
      randomly allocated to receive ch14.18 manufactured by UTC or NCI during Courses 1 and 2
      followed by ch14.18 manufactured by other manufacturer (UTC or NCI) during Courses 3, 4, and
      5.
    
  